跳至主要内容
临床试验/CTRI/2013/05/003683
CTRI/2013/05/003683已完成4 期

Evaluation of the Effectiveness, Safety and Tolerability of Dhathri Fair Skin Cream in Imparting Skin Fairness, Reduction of Black Spots and Dark Circles Under Eyes in Human Adults

Dhathri Ayurveda Private Limited0 个研究点目标入组 36 人开始时间: 待定最近更新:

试验速览

阶段
4 期
状态
已完成
入组人数
36

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1. Healthy Male and female subjects aged between
  • 18 and 35 years.
  • 2. Subjects who can read, understand, give written informed consent form and who are willing to comply with the study protocol.
  • 3. Subjects of skin grade III, IV, and V (Fitzpatrick Scale).
  • 4. Subjects with any type of skin like oily, normal and dry.
  • 5. Subjects having at least any one of the following: black spots, dark circles under eyes. (Minimum 5 subjects with black spots and Minimum 5 subjects with dark circles under eyes)
  • 6. Subjects showing negative to sensitivity test.
  • 7. Subject who has not participated in a similar investigation in the past four weeks.
  • 8. Subjects having pigmentation freckles, pigmented demarcation lines, and uneven tone skin will also be included.

排除标准

  • 1. Women who are pregnant or lactating.
  • 2. A known history or present condition of allergic response to any cosmetic products.
  • 3. Subjects with a history of Insomnia or sleeplessness.
  • 4. Subject having skin diseases (e.g. moderate to severe acne vulgaris face, psoriasis, active atopic dermatitis, melasma, which will interfere with the test readings.
  • 5. Subjects on oral medications (e.g. steroids, anti-oxidant) which will compromise the study.
  • 6. Systemic treatment of the skin that may change the state of the skin, in the previous 30 days.
  • 7. Subjects not willing to discontinue other fairness/whitening/ brightening creams including vitamin A derivatives.
  • 8. Subjects showing allergic reactions to any component of the tested products.
  • 9. Subjects who has a history of intense sun exposure.
  • 10. Chronic illness which may influence the cutaneous state of the skin.
  • 11. Subject participating in any other cosmetic or therapeutic trial.

研究者

相似试验

进行中(未招募)
1 期
Evaluation of the effectiveness, safety, and tolerability of tapentadol PR versus a combination of tapentadol PR and pregabalin in subjects with severe chronic low back pain with a neuropathic pain componentsevere chronic low back pain with a neuropathic pain componentMedDRA version: 12.1Level: LLTClassification code 10024891Term: Low back painMedDRA version: 12.1Level: LLTClassification code 10054095Term: Neuropathic pain
EUCTR2010-019998-14-BEGrünenthal GmbH800
进行中(未招募)
不适用
Comparison of tapentadol PR and oxycodone/naloxone PR
EUCTR2012-002943-11-ITGrünenthal GmbH240
进行中(未招募)
不适用
Evaluation of the effectiveness, safety, and tolerability of tapentadol PR versus a combination of tapentadol PR and pregabalin in subjects with severe chronic low back pain with a neuropathic pain componentsevere chronic low back pain with a neuropathic pain componentMedDRA version: 12.1Level: LLTClassification code 10024891Term: Low back painMedDRA version: 12.1Level: LLTClassification code 10054095Term: Neuropathic pain
EUCTR2010-019998-14-NLGrünenthal GmbH800
进行中(未招募)
不适用
Comparison of increasing doses of tapentadol vs a combination of tapentadol and pregabaliSevere chronic low back pain with a neuropathic pain componentMedDRA version: 14.0Level: LLTClassification code 10054095Term: Neuropathic painSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 14.0Level: LLTClassification code 10024891Term: Low back painSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disorders
EUCTR2010-019998-14-ATGrünenthal GmbH800
已完成
3 期
Evaluation of the effectiveness, safety, and tolerability of tapentadol PR versus a combination of tapentadol PR and pregabalin in subjects with severe chronic low back pain with a neuropathic pain componenternstig chronische lage rugpijn met een neuropatische componentneuropatic pain and low back pain
NL-OMON36404Grunenthal50
Study to Assess the Effectiveness and Safety of... | 临床试验